Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Holdings Boosted by Fiera Capital Corp

Fiera Capital Corp lifted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 1.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 480,409 shares of the company’s stock after buying an additional 4,899 shares during the period. Fiera Capital Corp owned about 0.61% of Crinetics Pharmaceuticals worth $21,518,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CRNX. Russell Investments Group Ltd. increased its stake in Crinetics Pharmaceuticals by 366,571.4% in the 1st quarter. Russell Investments Group Ltd. now owns 51,334 shares of the company’s stock valued at $2,403,000 after buying an additional 51,320 shares during the period. Swiss National Bank increased its stake in shares of Crinetics Pharmaceuticals by 21.4% in the first quarter. Swiss National Bank now owns 126,500 shares of the company’s stock worth $5,921,000 after acquiring an additional 22,300 shares during the last quarter. Vanguard Group Inc. grew its stake in Crinetics Pharmaceuticals by 2.1% in the first quarter. Vanguard Group Inc. now owns 3,575,076 shares of the company’s stock valued at $167,349,000 after purchasing an additional 72,624 shares in the last quarter. First Light Asset Management LLC increased its position in Crinetics Pharmaceuticals by 25.5% in the 4th quarter. First Light Asset Management LLC now owns 1,987,772 shares of the company’s stock worth $70,725,000 after purchasing an additional 404,443 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of Crinetics Pharmaceuticals by 1,224.8% during the 2nd quarter. SG Americas Securities LLC now owns 79,051 shares of the company’s stock worth $3,541,000 after purchasing an additional 73,084 shares in the last quarter. 98.51% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, insider Stephen F. Betz sold 3,000 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $43.86, for a total value of $131,580.00. Following the transaction, the insider now owns 83,643 shares of the company’s stock, valued at $3,668,581.98. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Stephen F. Betz sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $43.86, for a total transaction of $131,580.00. Following the transaction, the insider now directly owns 83,643 shares in the company, valued at $3,668,581.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dana Pizzuti sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $45.73, for a total transaction of $434,435.00. Following the completion of the sale, the insider now directly owns 27,786 shares of the company’s stock, valued at approximately $1,270,653.78. The disclosure for this sale can be found here. Insiders sold 170,016 shares of company stock valued at $8,337,942 in the last three months. Corporate insiders own 6.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CRNX. Robert W. Baird raised their price objective on shares of Crinetics Pharmaceuticals from $52.00 to $62.00 and gave the company an “outperform” rating in a research report on Thursday, May 23rd. Oppenheimer reissued an “outperform” rating and set a $73.00 target price (down from $74.00) on shares of Crinetics Pharmaceuticals in a research report on Friday, August 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $97.00 price target on shares of Crinetics Pharmaceuticals in a research report on Tuesday, July 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Crinetics Pharmaceuticals in a report on Tuesday, May 14th. Finally, JMP Securities reiterated a “market outperform” rating and set a $80.00 price target on shares of Crinetics Pharmaceuticals in a report on Tuesday, June 4th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, Crinetics Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.75.

Crinetics Pharmaceuticals Stock Down 2.0 %

NASDAQ:CRNX opened at $52.02 on Wednesday. The firm has a 50-day moving average price of $50.92 and a 200 day moving average price of $46.96. The firm has a market capitalization of $4.16 billion, a PE ratio of -13.76 and a beta of 0.68. Crinetics Pharmaceuticals, Inc. has a 12-month low of $15.76 and a 12-month high of $55.78.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.08). The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.47 million. During the same period in the prior year, the company earned ($0.94) EPS. Crinetics Pharmaceuticals’s quarterly revenue was down 59.6% on a year-over-year basis. On average, research analysts expect that Crinetics Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Crinetics Pharmaceuticals Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.